Indoco Remedies gets US FDA approval for lacosamide injection
Indoco Remedies Ltd. announced that the United States Food & Drug Administration (FDA) has approved the ANDA lacosamide injection USP, 200 mg/20 mL (10 mg/mL) single-dose vials. The generic lacosamide injection USP of Indoco Remedies is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Vimpat injection of UCB, Inc.
Lacosamide injection is indicated for the prevention and control of seizures. It is an anticonvulsant/antiepileptic drug.
Commenting on the development, Aditi Kare Panandikar, managing director-Indoco Remedies said,
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!